Navigation Links
Prostate cancer vaccines more effective with hormone therapy
Date:7/9/2008

PHILADELPHIA Among patients with castration-resistant prostate cancer, the addition of hormone therapy following vaccine treatment improved overall survival compared with either treatment alone or when the vaccine followed hormone treatment, according to recent data published in the July 15 Clinical Cancer Research, a journal of the American Association for Cancer Research.

Philip M. Arlen, M.D., director of the Clinical Research Group for the Laboratory of Tumor Immunology and Biology, Center for Cancer Research, at the National Cancer Institute, said the findings have important implications for guiding treatment decisions for prostate cancer patients.

"Vaccines, if and when they are approved, can be safely and effectively combined with other therapies, including hormones," said Arlen. "There appears to be an advantage in overall survival."

Arlen and colleagues enrolled 42 patients who had castration-resistant prostate cancer. These patients were randomly assigned to receive either a poxvirus-based prostate-specific antigen vaccine or hormone therapy with nilutamide. At progression, patients received the other therapy and continued to receive their original therapy.

For all the patients enrolled in the study, the three-year survival probability was 71 percent and the median overall survival was 4.4 years. Patients randomized to the vaccine had a three-year survival probability of 81 percent and an overall survival of 5.1 years, while patients taking nilutamide had a three-year survival probability of 62 percent and an overall survival of 3.4 years.

Of the 42 patients in the study, 12 patients who were originally assigned to vaccine switched to nilutamide plus vaccine and eight patients who were originally assigned to nilutamide switched to vaccine plus hormone, due to rising levels of prostate-specific antigen with no evidence of metastasis. For patients who received vaccine and then nilutamide, the three-year survival probability was 100 percent with a median overall survival of 6.2 years. For patients who switched to the vaccine after hormone, the three-year survival probability was 75 percent with a median overall survival of 3.7 years.

Arlen said the hormone therapy in combination with the vaccine works in two ways.

"By using hormone therapy in prostate cancer you can help enhance your T-cell response to where the cancer is in the prostate gland, and you are also more likely to achieve a better immune response," said Arlen.

Building on the results of this phase II study, researchers have developed another generation of this vaccine by adding molecules which boost T-cell responses.

Based on the current pace of vaccine research overall, Arlen predicts that men with prostate cancer could potentially see an effective, new treatment vaccine within the next several years.

"Phase II trials such as this one are adding to our knowledge, and other phase III trials are getting ready to publish their data," said Arlen. "If the phase II data hold up in phase III trials, we could see a new treatment vaccine within a few years."


'/>"/>

Contact: Jeremy Moore
Jeremy.moore@aacr.org
267-646-0557
American Association for Cancer Research
Source:Eurekalert

Related biology news :

1. Counting tumor cells in blood predicts treatment benefit in prostate cancer
2. Urologists identify 7 biomarkers that may help pinpoint prostate cancer recurrence
3. Certain form of tomatoes could be key to prostate cancer prevention
4. Estrogen helps drive distinct, aggressive form of prostate cancer
5. Genes may play role in risk assessment for prostate cancer among Hispanics and caucasians
6. Biomarker predicts malignancy potential of HG-PIN lesions in the prostate
7. Potential association of type 2 diabetes genes with prostate cancer
8. New, noninvasive prostate cancer test beats PSA in detecting prostate cancer
9. Prostate cancer: Watchful wait or vaccinate?
10. Nanomedicine research for prostate cancer supported by $5 million gift
11. Safeway Inc. and PCF to fund landmark prostate cancer research collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/7/2017)... , March 7, 2017 Brandwatch , the ... by The Prince,s Trust to uncover insights to support ... The Trust. The UK,s leading youth charity will be ... campaign results and get a better understanding of the topics and ... ...
(Date:3/2/2017)... 2017 Who risk to be deprived of ... full report: https://www.reportbuyer.com/product/4313699/ WILL APPLE AND ... Fingerprint sensors using capacitive technology represent a fast ... Idex forecasts an increase of 360% of the number ... the fingerprint sensor market between 2014 and 2017 (source ...
(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ein ... wird seine erstklassige biometrische Lösung zur Iris-Erkennung ... mit X16 LTE auf dem Mobile World ... am Qualcomm-Stand in Halle 3, Stand 3E10, ... die Sicherheitsplattform Qualcomm Haven™ – eine Kombination ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... , March 27, 2017 Cousins Properties (NYSE: ... world,s leading biotechnology companies, has signed a 10-year, approximately 125,000 ... A office asset located in the Westshore submarket of ... thrilled that Amgen has chosen Corporate Center for their new ... Gellerstedt , president and chief executive officer of Cousins Properties. ...
(Date:3/27/2017)... March 27, 2017 Infectex Ltd., a Russian portfolio company of ... study of SQ109 added to the standard drug therapy regimen in patients with multidrug-resistant ... Sequella, Inc. ( USA ) and the US National Institutes of Health. ... ... Biotech Venture Fund Logo ...
(Date:3/27/2017)... Va. , March 27, 2017  Perthera,s Chief ... Cancer Center, Subha Madhavan , Ph.D., will be ... Joint Summits Panels. On Monday, March 27, 2017, she ... Oncology Data More Usable for Research and Care" (from ... March 28, 2017, she will be a participant in ...
(Date:3/27/2017)... ... 2017 , ... PMG Research is pleased to announce its participation ... Conference Forum in Boston on April 3-4, 2017. The CTC conference focuses on how ... and bring them closer to the patient. Clinical Trial Collaborations also will present an ...
Breaking Biology Technology: